$1.54 EPS Expected for Waters Co. (WAT) This Quarter

Wall Street brokerages expect Waters Co. (NYSE:WAT) to post earnings per share of $1.54 for the current quarter, Zacks Investment Research reports. Eight analysts have made estimates for Waters’ earnings, with the lowest EPS estimate coming in at $1.52 and the highest estimate coming in at $1.57. Waters posted earnings per share of $1.46 in the same quarter last year, which would suggest a positive year over year growth rate of 5.5%. The company is scheduled to report its next quarterly earnings report on Tuesday, April 24th.

According to Zacks, analysts expect that Waters will report full year earnings of $8.16 per share for the current financial year, with EPS estimates ranging from $8.10 to $8.23. For the next year, analysts anticipate that the firm will report earnings of $8.96 per share, with EPS estimates ranging from $8.80 to $9.08. Zacks’ EPS calculations are an average based on a survey of research firms that that provide coverage for Waters.

Waters (NYSE:WAT) last posted its earnings results on Tuesday, January 23rd. The medical instruments supplier reported $2.51 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.44 by $0.07. Waters had a return on equity of 24.70% and a net margin of 0.88%. The company had revenue of $687.28 million for the quarter, compared to analyst estimates of $671.98 million. During the same period last year, the company earned $2.21 earnings per share. The business’s revenue was up 9.3% compared to the same quarter last year.

Several research firms have weighed in on WAT. Morgan Stanley upgraded Waters from an “underweight” rating to an “equal weight” rating and set a $192.00 target price on the stock in a report on Monday, December 4th. Evercore ISI began coverage on Waters in a report on Wednesday, January 3rd. They set an “in-line” rating and a $198.00 target price on the stock. William Blair restated an “outperform” rating on shares of Waters in a report on Tuesday, January 23rd. BTIG Research restated a “buy” rating on shares of Waters in a report on Thursday, January 25th. Finally, Zacks Investment Research upgraded Waters from a “hold” rating to a “buy” rating and set a $217.00 target price on the stock in a report on Tuesday, December 26th. Twelve equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $203.75.

In other news, SVP Elizabeth B. Rae sold 28,400 shares of the firm’s stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $219.01, for a total value of $6,219,884.00. Following the sale, the senior vice president now directly owns 13,443 shares of the company’s stock, valued at $2,944,151.43. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP David Terricciano sold 21,997 shares of the firm’s stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $197.52, for a total value of $4,344,847.44. Following the completion of the sale, the senior vice president now directly owns 9,173 shares in the company, valued at $1,811,850.96. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 121,289 shares of company stock worth $25,383,542. 5.07% of the stock is currently owned by company insiders.

Several large investors have recently modified their holdings of the company. Advisory Services Network LLC grew its position in Waters by 6.0% during the second quarter. Advisory Services Network LLC now owns 1,145 shares of the medical instruments supplier’s stock worth $210,000 after buying an additional 65 shares in the last quarter. Raymond James Financial Services Advisors Inc. grew its position in Waters by 3.0% during the second quarter. Raymond James Financial Services Advisors Inc. now owns 6,668 shares of the medical instruments supplier’s stock worth $1,226,000 after buying an additional 196 shares in the last quarter. Advisor Partners LLC grew its position in Waters by 11.6% during the fourth quarter. Advisor Partners LLC now owns 2,372 shares of the medical instruments supplier’s stock worth $500,000 after buying an additional 246 shares in the last quarter. Nisa Investment Advisors LLC grew its position in Waters by 0.5% during the fourth quarter. Nisa Investment Advisors LLC now owns 46,545 shares of the medical instruments supplier’s stock worth $8,992,000 after buying an additional 253 shares in the last quarter. Finally, LS Investment Advisors LLC grew its position in Waters by 7.0% during the fourth quarter. LS Investment Advisors LLC now owns 3,962 shares of the medical instruments supplier’s stock worth $765,000 after buying an additional 259 shares in the last quarter. 93.36% of the stock is currently owned by institutional investors.

Waters (WAT) traded up $2.16 during midday trading on Monday, reaching $206.39. The company’s stock had a trading volume of 84,615 shares, compared to its average volume of 525,800. Waters has a one year low of $152.05 and a one year high of $220.20. The company has a current ratio of 2.10, a quick ratio of 1.97 and a debt-to-equity ratio of 0.66. The company has a market capitalization of $16,214.40, a price-to-earnings ratio of 27.18, a P/E/G ratio of 2.44 and a beta of 0.88.

WARNING: This news story was first posted by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright legislation. The correct version of this news story can be accessed at https://stocknewstimes.com/2018/02/22/1-54-eps-expected-for-waters-co-wat-this-quarter.html.

About Waters

Waters Corporation is an analytical instrument manufacturer. The Company operates through two segments: Waters and TA. It designs, manufactures, sells and services high performance liquid chromatography (HPLC), ultra performance liquid chromatography (UPLC and together with HPLC, referred to as LC) and mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products and post-warranty service plans.

Get a free copy of the Zacks research report on Waters (WAT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Waters (NYSE:WAT)

Receive News & Ratings for Waters Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Waters and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply